The Pharmacy and Poisons Board PPB has issued a nationwide alert regarding substandard batches of Paracetamol 1000mg/100ml injection found in the market. The affected products marketed under the brand names Lumidol, Blink, and Paragen have shown visible color changes, raising concerns about their quality and safety.
In an official statement released on Thursday, the Board identified the compromised batches as: Lumidol Injection – Batch numbers CM4594007, CM4594008, CM4594009, Blink Injection – Batch numbers CS4594005, CS4594004, Paragen Injection – Batch number K4290027.
All affected products were manufactured by KamlaAmrut Pharmaceutical LLP, based in India.
The Board has directed all pharmaceutical outlets, healthcare facilities, and professionals to immediately cease distribution, sale, issuance, or use of the listed batches. Members of the public are also advised to return any affected products to the nearest health facility or supplier.
“The safety and efficacy of medical products is paramount. We urge all stakeholders to take this alert seriously to safeguard public health,” said Dr. F. M. Siyoi, Chief Executive Officer of the Pharmacy and Poisons Board.
Consumers and healthcare professionals are encouraged to report any cases of suspected substandard medicines or adverse drug reactions through : Online portal: pv.pharmacyboardkenya.org,USSD: *271#, Email: pv@ppb.go.ke / pms@ppb.go.ke and telephone: 0795743049.
Siyoi said, the Board is committed to ensuring the safety and efficacy of medicines in the market to protect public health.
